Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111540 · ClinicalTrials.gov registry record · Phase 3
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT00111540 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 456 participants.
The verdict
NCT00111540, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
This open label study is designed to assess long term glucose control, as measured by hemoglobin A1c (HbA1c) and to evaluate long term safety and tolerability in subjects with type 2 diabetes mellitus who receive subcutaneously injected exenatide administered twice a day.
Interventions
- DRUG exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2002-11 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111540
The ClinicalTrials.gov registry entry for NCT00111540 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which exenatide is the first listed.
NCT00111540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111540 about?
NCT00111540 is a clinical study titled "Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes". This open label study is designed to assess long term glucose control, as measured by hemoglobin A1c (HbA1c) and to evaluate long term safety and tolerability in subjects with type 2 diabetes mellitus who receive subcutaneously injected exenatide administered twice a day.
What is the current status of trial NCT00111540?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2002-11. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00111540?
The interventions under investigation include: exenatide (DRUG).
Who is sponsoring clinical trial NCT00111540?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.